NOAC/DOAC Labeled Uses/Approved Indications Flashcards

1
Q

What are the FDA-approved indications for Dabigatran?

A

-Postoperative prophylaxis (hip)
-Non-valvular atrial fibrillation
-DVT/PE treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the FDA-approved indications for Rivaroxaban?

A

-Postoperative prophylaxis
-Non-valvular atrial fibrillation
-DVT/PE treatment
-Secondary prevention of recurrent DVT/PE
-VTE prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the FDA-approved indications for Apixaban?

A

-Postoperative prophylaxis
-Non-valvular atrial fibrillation
-DVT/PE treatment
-Secondary prevention of recurrent DVT/PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the FDA-approved indications for Edoxaban?

A

-Non-valvular atrial fibrillation
-DVT/PE treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do you define the labeled use of postoperative prophylaxis?

A

-Postoperative thromboprophylaxis of DVT which may lead to PE in patients undergoing KNEE OR HIP replacement surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do you define the labeled use of non-valvular atrial fibrillation?

A

-Prevention of stroke and systemic embolism in patients with NON-VALVULAR atrial fibrillation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do you define the labeled use of DVT/PE treatment?

A

-Treatment of DVT/PE (straightforward)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do you define the labeled use of VTE prophylaxis?

A

-Prophylaxis of VTE in adults HOSPITALIZED FOR AN ACUTE MEDICAL ILLNESS who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do you define the labeled use of secondary prevention of recurrent DVT and/or PE?

A

-Reduction in the risk of recurrence of DVT and PE FOLLOWING INITIAL 6 MONTHS OF TREATMENT for DVT and/or PE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the NOACs/DOACs

A

-Dabigatran etexilate (Pradaxa)
-Rivaroxaban (Xarelto)
-Apixaban (Eliquis)
-Edoxaban (Savaysa)
-Betrixaban (Bevyxxa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which NOACs/DOACs are BID dosing for atrial fibrillation?

A

-Dabigatran
-Apixaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which NOACs/DOACs are once-daily dosing for atrial fibrillation?

A

-Rivaroxaban
-Edoxaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does apixaban differ from the other NOACs in renal adjustment?

A

Apixaban is the only medication that is adjusted based on SCr instead of CrCl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which two criteria must be met in order to warrant dose adjustment for apixaban when treating non-valvular atrial fibrillation?

A

-Age of 80 or older
-body weight of 60kg or less
-SCr of 1.5 or more

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When is it not recommended to use edoxaban?

A

When the CrCl is above 95

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which drugs require 5-10 days of parenteral anticoagulation AFTER d/c?

A

-Dabigatran
-Edoxaban

17
Q

Which two medications are recommended for use in the secondary prevention of recurrent DVT/PE after the initial 6 months of treatment?

A

-Rivaroxaban
-Apixaban

18
Q

What is the only drug recommended for VTE prophylaxis?

A

Rivaroxaban